Harrow, Inc. (HROW) income statement
HROWNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 6/30927% above fair value
$30.41−1.72 (-5.35%)
Close on Nov 20, 2026Market cap $1.14BP/E –Yield –
Harrow, Inc. financial ratios
See a number that looks wrong?